Breaking News Instant updates and real-time market news.

DXCM

DexCom

$130.70

-2.8 (-2.10%)

, ABT

Abbott

$73.81

-0.34 (-0.46%)

14:48
10/02/18
10/02
14:48
10/02/18
14:48

Abbott's Libre sensor prices 'creeping higher,' says Piper Jaffray

Piper Jaffray analyst JP McKim noted that his tracking of the weekly price of Abbott's (ABT) FreeStyle Libre Sensors indicates that prices have risen over the last four weeks by varying amounts depending on the area of the country, but "no matter what area, prices have gone up." He reads this as evidence that the "aggressive pharmacy discounting" Abbott did in the early launch days are coming to an end and reiterates his previously communicated belief that CGM demand has hit an inflection point and that the market has room for multiple players, including both Abbott and DexCom (DXCM). McKim keeps an Overweight rating on DexCom shares.

DXCM

DexCom

$130.70

-2.8 (-2.10%)

ABT

Abbott

$73.81

-0.34 (-0.46%)

  • 03

    Oct

  • 17

    Oct

DXCM DexCom
$130.70

-2.8 (-2.10%)

09/18/18
PIPR
09/18/18
NO CHANGE
Target $150
PIPR
Overweight
DexCom supply constraints getting better, says Piper Jaffray
Piper Jaffray analyst JP McKim says his latest channel checks on DexCom (DXCM) show that supply is still constrained but getting better. Further, the checks indicate that Abbott's (ABT) Libre 14 day sensor is the same price as the 10 day on a per day basis and should be launching in the next month, McKim tells investors in a research note. While it is "too soon to blow the all clear horn" on DexCom's supply issues, things are "improving steadily" and the demand for the company's G6 remains robust, the analyst contends. He believes the continuous glucose monitoring market is "really taking off" and expects continued strong results from DexCom in both Q3 and Q4. McKim keeps an Overweight rating on the shares with a $150 price target.
09/18/18
LEER
09/18/18
NO CHANGE
Target $170
LEER
Outperform
Leerink sees continued upside in shares of DexCom
Leerink analyst Danielle Antalffy continues to see upside in shares of DexCom after hosting investor meetings with management. The meetings reinforced the analyst's confidence that near-term guidance beatable and that the Street continue to underestimate both the pace of adoption ramp in the current Type 1 patient population and DexCom's "still-strong" competitive advantage even as new entrants come to market. She believes the company's 2018 guidance is "extremely conservative" and reiterates an Outperform rating on the shares with a $170 price target.
09/18/18
LSCM
09/18/18
NO CHANGE
Target $60
LSCM
Buy
Tandem Diabetes recent selloff a buying opportunity, says Lake Street
Lake Street analyst Brooks O'Neil views the recent pullback in shares of Tandem Diabetes (TNDM) as a buying opportunity. The analyst believes the stock is 'just getting going" and that the recent correction is healthy. The revolution underway in diabetes management today involves using innovative technology to monitor and adjust a diabetic's blood sugars automatically in an effort to keep them "in range," O'Neil tells investors in a research note. He believes Tandem is leading this revolution in conjunction with its partner, Dexcom (DXCM), and that it is in the early stages. The analyst recommends buying Tandem ahead of what he thinks will be the "next big run" in the stock. O'Neil keeps a Buy rating on the name with a $60 price target.
10/01/18
PIPR
10/01/18
NO CHANGE
PIPR
Overweight
Abbott news a negative headline for DexCom, says Piper Jaffray
Abbott Laboratories (ABT) this morning announced CE Mark approval of Libre 2, which provides optional real-time alarms at no additional cost compared to Libre 1, Piper Jaffray analyst JP McKim tells investors in a research note. From the analyst's understanding, users still have to scan the device for a reading but can have the system alert the user for hypo and/or hyper events customized by the user. Abbott is now one step closer to looking like a DexCom (DXCM), "though still not all the way there," McKim contends. Nonetheless, the analyst admits this morning's headline is a negative for DexCom. He still believes, however, that DexCom should continue to outpace consensus growth for several quarters. He keeps an Overweight rating on the shares. The stock in early trading is down 4%, or $5.78, to $137.26.
ABT Abbott
$73.81

-0.34 (-0.46%)

09/24/18
MSCO
09/24/18
NO CHANGE
Target $70
MSCO
Overweight
Abbott's COAPT 'wildly surpassed expectations,' says Morgan Stanley
Morgan Stanley analyst David Lewis said data from the Abbott's COAPT trial comparing Mitraclip with guideline-determined medical therapy against GDMT alone "wildly surpassed expectations" and he expects a sharp inflection in utilization. Lewis, who called this "one of the cleanest and strongest datasets in the history of interventional cardiology," estimates Mitraclip procedures could increase to about 22,000 procedures over 2-4 years, implying U.S. sales of about $250M today can increase to over $550M. He maintains an Overweight rating and $70 price target on Abbott shares, which are up about 3% to $71 in pre-market trading.
09/24/18
COWN
09/24/18
NO CHANGE
Target $72
COWN
Outperform
Abbott Mitraclip data a 'grand slam,' says Cowen
Cowen analyst Joshua Jennings said the Abbott COAPT trial results meaningfully outperformed skeptical consensus expectations with Mitraclip generating statistically significant decreases in the rates of both heart failure hospitalizations and all-cause mortality. The analyst said the results are so strong that COAPT now represents a landmark study for functional mitral regurgitation and reemphasizes Abbott's leadership in TMV repair. Jennings reiterated his Outperform rating and $72 price target on Abbott shares.

TODAY'S FREE FLY STORIES

OHRP

Ohr Pharmaceutical

$2.01

(0.00%)

10:47
02/21/19
02/21
10:47
02/21/19
10:47
Hot Stocks
Ohr Pharmaceutical regains compliance with Nasdaq listing requirements »

Ohr Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMDZ

Immune Design

$5.81

4.385 (307.72%)

, MRK

Merck

$79.79

0.35 (0.44%)

10:46
02/21/19
02/21
10:46
02/21/19
10:46
Downgrade
Immune Design, Merck rating change  »

Immune Design downgraded…

IMDZ

Immune Design

$5.81

4.385 (307.72%)

MRK

Merck

$79.79

0.35 (0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Mar

  • 11

    Apr

  • 18

    May

  • 17

    Jun

10:45
02/21/19
02/21
10:45
02/21/19
10:45
General news
Breaking General news story  »

3-Month Bill Announcement…

10:45
02/21/19
02/21
10:45
02/21/19
10:45
General news
Breaking General news story  »

6-Month Bill Announcement…

ANET

Arista Networks

$266.95

-3.58 (-1.32%)

10:45
02/21/19
02/21
10:45
02/21/19
10:45
Conference/Events
Arista Networks has a conference call hosted by JPMorgan »

JPMorgan Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 25

    Feb

  • 25

    Feb

  • 25

    Feb

  • 25

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 04

    Mar

  • 12

    Mar

  • 13

    Mar

  • 13

    Mar

10:45
02/21/19
02/21
10:45
02/21/19
10:45
General news
Breaking General news story  »

Week of 2/15 EIA…

NKE

Nike

$83.97

-0.87 (-1.03%)

10:40
02/21/19
02/21
10:40
02/21/19
10:40
On The Fly
Analyst sees 'minimal' lasting damage to Nike brand after Duke star's shoe splits »

Shares of Nike (NKE)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFT

Weatherford

$0.79

-0.0263 (-3.21%)

10:40
02/21/19
02/21
10:40
02/21/19
10:40
Options
10.1K Weatherford Mar 1 calls trade as shares drop 2c to 80c »

10.1K Weatherford Mar 1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

10:40
02/21/19
02/21
10:40
02/21/19
10:40
General news
Treasury Action: yields have cheapened despite some disappointing data »

Treasury Action: yields…

KAR

KAR Auction

$48.30

1.56 (3.34%)

10:37
02/21/19
02/21
10:37
02/21/19
10:37
Upgrade
KAR Auction rating change  »

KAR Auction upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 07

    Mar

  • 13

    Mar

  • 14

    Mar

NCLH

Norwegian Cruise Line

$55.71

1.99 (3.70%)

10:32
02/21/19
02/21
10:32
02/21/19
10:32
Recommendations
Norwegian Cruise Line analyst commentary  »

Buckingham says backdrop…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 03

    Mar

  • 28

    May

BSX

Boston Scientific

$40.03

-0.1 (-0.25%)

10:30
02/21/19
02/21
10:30
02/21/19
10:30
Options
Bullish option flow in Boston Scientific »

Bullish option flow in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 06

    Mar

  • 18

    May

  • 28

    May

SNPS

Synopsys

$100.68

-2.3 (-2.23%)

10:26
02/21/19
02/21
10:26
02/21/19
10:26
Recommendations
Synopsys analyst commentary  »

Synopsys weakness a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 25

    Feb

  • 26

    Feb

  • 26

    Feb

  • 03

    Mar

  • 08

    Mar

  • 14

    Mar

  • 17

    Mar

  • 16

    Jul

  • 17

    Jul

  • 26

    Sep

  • 27

    Sep

NWL

Newell Brands

$17.18

0.05 (0.29%)

10:25
02/21/19
02/21
10:25
02/21/19
10:25
Periodicals
Newell Brands CEO faces board pressure following poor sales, WSJ reports »

Newell Brands CEO Michael…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

10:25
02/21/19
02/21
10:25
02/21/19
10:25
Conference/Events
Morgan Stanley consumer goods analysts to hold analyst/industry conference call »

Executive Director of…

BIIB

Biogen

$323.78

-11.23 (-3.35%)

, ESALY

Eisai

$0.00

(0.00%)

10:25
02/21/19
02/21
10:25
02/21/19
10:25
Conference/Events
JPMorgan large-cap biotech analysts to hold an analyst/industry conference call »

Large Cap Biotech Analyst…

BIIB

Biogen

$323.78

-11.23 (-3.35%)

ESALY

Eisai

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 25

    Feb

  • 28

    May

10:25
02/21/19
02/21
10:25
02/21/19
10:25
Conference/Events
JPMorgan retail analysts to hold an analyst/industry conference call »

Retail Analysts Boss and…

10:25
02/21/19
02/21
10:25
02/21/19
10:25
Conference/Events
Morgan Stanley sports/footwear analyst to hold analyst/industry conference call »

Sports & Footwear…

EEM

iShares MSCI Emerging Markets ETF

$42.48

-0.175 (-0.41%)

10:20
02/21/19
02/21
10:20
02/21/19
10:20
Options
Size three-way spread in iShares Emerging Markets Fund as shares tick lower »

Size three-way spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
02/21/19
02/21
10:17
02/21/19
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
02/21/19
02/21
10:16
02/21/19
10:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:15
02/21/19
02/21
10:15
02/21/19
10:15
General news
U.S. leading index dipped 0.1% to 111.3 in January »

U.S. leading index dipped…

10:15
02/21/19
02/21
10:15
02/21/19
10:15
General news
Breaking General news story  »

Week of 2/15 EIA Natural…

HOME

At Home Group

$23.84

0.01 (0.04%)

, HLIT

Harmonic

$5.51

0.19 (3.57%)

10:11
02/21/19
02/21
10:11
02/21/19
10:11
Initiation
Fly Intel: Top five analyst initiations »

Catch up on today's…

HOME

At Home Group

$23.84

0.01 (0.04%)

HLIT

Harmonic

$5.51

0.19 (3.57%)

ATKR

Atkore

$24.08

-0.09 (-0.37%)

BTX

BioTime

$1.24

0.08 (6.90%)

VRCA

Verrica Pharmaceuticals

$10.99

(0.00%)

APHA

Aphria

$10.40

0.24 (2.36%)

KSHB

KushCo Holdings

$0.00

(0.00%)

HEXO

HEXO Corp

$6.11

0.13 (2.17%)

CGC

Canopy Growth

$45.44

-0.74 (-1.60%)

ACB

Aurora Cannabis

$7.18

0.12 (1.70%)

TLRY

Tilray

$80.25

-0.82 (-1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 26

    Feb

  • 01

    Mar

  • 07

    Mar

  • 18

    Mar

  • 18

    Mar

GRMN

Garmin

$82.02

-1 (-1.20%)

, BIIB

Biogen

$324.13

-10.88 (-3.25%)

10:11
02/21/19
02/21
10:11
02/21/19
10:11
Downgrade
Fly Intel: Top five analyst downgrades »

Catch up on today's…

GRMN

Garmin

$82.02

-1 (-1.20%)

BIIB

Biogen

$324.13

-10.88 (-3.25%)

FARO

Faro Technologies

$45.51

1.73 (3.95%)

DHI

D.R. Horton

$39.91

0.04 (0.10%)

LEN

Lennar

$49.12

0.16 (0.33%)

GIS

General Mills

$46.68

-0.26 (-0.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 25

    Feb

  • 25

    Feb

  • 28

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.